89bio presents new data from phase 1b/2a nash study showing bio89-100 reduces spleen volume

New sub-analysis presented at the liver meeting ® 2021 shows treatment with bio89-100 reduced spleen volume by an average of 11.8% in nash patients

ETNB Ratings Summary

ETNB Quant Ranking